Kenya Participates in Landmark Tuberculosis Vaccine Trial
Nairobi, The Gulf Observer: Kenya is among three countries involved in a major tuberculosis (TB) vaccine trial aimed at enhancing the efficacy of the Bacillus Calmette-Guérin (BCG) vaccine, which has been in use for over a century.
The trials in Kenya will be conducted by scientists from the Kenya Medical Research Institute (Kemri) and the Centre for Respiratory Disease Research in Nairobi. The study will be carried out across 15 sites in South Africa, Kenya, and Tanzania.
The BCG vaccine, introduced more than 100 years ago, is currently the only approved TB vaccine. While it provides partial protection in children, it does not effectively prevent TB disease in adolescents and adults. The new trial seeks to address this limitation by developing a more effective vaccine against the disease.
Kenya’s participation in the study highlights its commitment to advancing medical research and strengthening public health interventions in the fight against TB, a disease that remains a significant global health challenge.
